Acute chest pain (ACP) is a common symptom that requires immediate attention due to its potential life-threatening implications. In modern healthcare, the management of ACP has significantly evolved, with an emphasis on prompt diagnosis and treatment to reduce morbidity and mortality.
The initial step in managing ACP involves a thorough history and physical examination, along with an electrocardiogram (ECG). The use of risk stratification tools, such as the HEART score, can aid in identifying high-risk patients who may benefit from immediate intervention.
Modern healthcare has witnessed the rise of novel biomarkers like High-Sensitivity Troponin (hs-cTn) which have improved the diagnostic accuracy of acute coronary syndrome (ACS). Additionally, advanced imaging modalities such as coronary CT angiography provide a non-invasive method for visualizing coronary artery disease.
The management of ACP includes both pharmacological and non-pharmacological strategies. Pharmacological interventions encompass nitrates, beta-blockers, and antiplatelet agents. Non-pharmacological interventions include lifestyle modifications and cardiac rehabilitation. In cases of ST-segment elevation myocardial infarction (STEMI), primary percutaneous coronary intervention (PCI) remains the treatment of choice.
The management of ACP is a multidisciplinary effort, involving cardiologists, emergency physicians, nurses, and pharmacists. The implementation of chest pain units (CPUs) in hospitals has shown to improve patient outcomes through rapid assessment and treatment.
In conclusion, the modern approach to managing ACP requires a combination of clinical assessment, risk stratification, advanced diagnostics, and prompt treatment strategies. A multidisciplinary team approach is crucial to ensure optimal patient care. As our understanding of ACP continues to evolve, it is essential for healthcare professionals to stay abreast of the latest guidelines and research in this field.
1.
High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy
2.
Papillary thyroid cancer: New markers offer hope for tailored treatment
3.
What Comes After Cancer?
4.
FDA Expands Durvalumab Label to Operable Lung Cancer
5.
In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.
1.
Finding Support: Connecting with the Vitiligo Community
2.
Essential Updates in Hematology in Daily Practice
3.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
4.
Living Better With Advanced Cancer Through Supportive Care
5.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
2.
Updates on Standard V/S High Risk Myeloma Treatment
3.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation